Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 8/2019

01-08-2019 | Computed Tomography | Thoracic Oncology

Tumor Volume Is Better Than Diameter for Predicting the Prognosis of Patients with Early-Stage Non-small Cell Lung Cancer

Authors: Hao-jun Xie, MS, Xu Zhang, MD, PhD, Yun-xian Mo, MD, Hao Long, MD, PhD, Tie-hua Rong, MD, Xiao-dong Su, MD, PhD

Published in: Annals of Surgical Oncology | Issue 8/2019

Login to get access

Abstract

Background

This study aimed to investigate whether tumor volume (TV) is better than diameter for predicting the prognosis of patients with early-stage non-small cell lung cancer (NSCLC) after complete resection.

Methods

This study retrospectively reviewed the clinicopathologic characteristics of 274 patients with early-stage NSCLC who had received pretreatment computed tomography (CT) scans and complete resection. TV was semi-automatically measured from CT scans using an imaging software program. The optimal cutoff of TV was determined by X-tile software. Disease-free survival (DFS) and overall survival (OS) were assessed by the Kaplan–Meier method. The prognostic significance of TV and other variables was assessed by Cox proportional hazards regression analysis.

Results

Using 3.046 cm3 and 8.078 cm3 as optimal cutoff values of TV, the patients were separated into three groups. A larger TV was significantly associated with poor DFS and OS in the multivariable analysis. Kaplan–Meier curves of DFS and OS showed significant differences on the basis of TV among patients with stage 1a disease, greatest tumor diameter (GTD) of 2 cm or smaller, and GTD of 2–3 cm, respectively. Using two TV cutoff points, three categories of TV were created. In 54 cases (19.7%), patients migrated from the GTD categories of 2 cm or smaller, 2–3 cm, and larger than 3 cm into the TV categories of 3.046 cm3 or smaller, 3.046–8.078 cm3, and larger than 8.078 cm3.

Conclusion

TV is an independent prognostic factor of DFS and OS for early-stage NSCLC. The findings show that TV is better than GTD for predicting the prognosis of patients with early-stage NSCLC.
Appendix
Available only for authorised users
Literature
1.
Rami-Porta R, Bolejack V, Crowley J, et al. The IASLC lung cancer staging project proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2015;10:990–1003.CrossRefPubMed
2.
Zhao B, Schwartz LH, Moskowitz CS, Ginsberg MS, Rizvi NA, Kris MG. Lung cancer: computerized quantification of tumor response: initial results. Radiology. 2006;241:892–8.CrossRefPubMed
3.
Suzuki C, Jacobsson H, Hatschek T. Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics. 2008;28:329–44.CrossRefPubMed
4.
Jennings SG, Winer-Muram HT, Tarver RD, Farber MO. Lung tumor growth: assessment with CT: comparison of diameter and cross-sectional area with volume measurements. Radiology. 2004;231:866–71.CrossRefPubMed
5.
Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39–51.CrossRefPubMed
6.
Gietema HA, Wang Y, Xu D, et al. Pulmonary nodules detected at lung cancer screening: interobserver variability of semiautomated volume measurements. Radiology. 2006;241:251–7.CrossRefPubMed
7.
7. Zhao B, Oxnard GR, Moskowitz CS, et al. A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clin Cancer Res. 2010;16:4647–53.CrossRefPubMedPubMedCentral
8.
8. Mozley PD, Schwartz LH, Bendtsen C, Zhao B, Petrick N, Buckler AJ. Change in lung tumor volume as a biomarker of treatment response: a critical review of the evidence. Ann Oncol. 2010;21:1751–5.CrossRefPubMed
9.
9. Mozley PD, Bendtsen C, Zhao B, et al. Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancer. Transl Oncol. 2012;5:19–25.CrossRefPubMedPubMedCentral
10.
10. Nishino M, Guo M, Jackman DM, et al. CT tumor volume measurement in advanced non-small cell lung cancer: performance characteristics of an emerging clinical tool. Acad Radiol. 2011;18:54–62.CrossRefPubMed
11.
11. Dehing-Oberije C, De Ruysscher D, van der Weide H, et al. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small cell lung cancer patients treated with (chemo) radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:1039–44.CrossRefPubMed
12.
12. Nishino M, Dahlberg SE, Cardarella S, et al. Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI. J Thorac Oncol. 2013;8:1059–68.CrossRefPubMedPubMedCentral
13.
13. Su XD, Xie HJ, Liu QW, Mo YX, Long H, Rong TH. The prognostic impact of tumor volume on stage I non-small cell lung cancer. Lung Cancer. 2017;104:91–7.CrossRefPubMed
14.
Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Pathology and genetics of tumours of the lung, pleura, thymus, and heart. In: World Health Organization classification of tumours. Lyon, France: IARC Press; 2004.
15.
15. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252–9.CrossRef
16.
16. Hyun SH, Choi JY, Kim K, et al. Volume-based parameters of 18 F-fluorodeoxy glucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection. Ann Surg. 2013;257:364–70.CrossRefPubMed
17.
17. Takenaka T, Yamazaki K, Miura N, Mori R, Takeo S. The prognostic impact of tumor volume in patients with clinical stage IA non-small cell lung cancer. J Thorac Oncol. 2016;11:1074–80.CrossRefPubMed
18.
Hyun SH, Ahn HK, Ahn MJ, et al. Volume-based assessment with 18F-FDG PET/CT improves outcome prediction for patients with stage IIIA-N2 non-small cell lung cancer. AJR Am J Roentgenol. 2015;205:623–8.CrossRefPubMed
19.
19. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552–9.CrossRefPubMed
20.
Scott WJ, Howington J, Feigenberg S, et al. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd ed). Chest. 2007;132:234S–42S.CrossRefPubMed
21.
Strauss GM, Herndon JE, Maddaus MA, et al.Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small cell lung cancer: CALGB 9633 with the cancer and leukemia group B, radiation therapy oncology group, and north central cancer treatment group study groups. J Clin Oncol. 2008;26:5043–51.CrossRefPubMedPubMedCentral
22.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMed
Metadata
Title
Tumor Volume Is Better Than Diameter for Predicting the Prognosis of Patients with Early-Stage Non-small Cell Lung Cancer
Authors
Hao-jun Xie, MS
Xu Zhang, MD, PhD
Yun-xian Mo, MD
Hao Long, MD, PhD
Tie-hua Rong, MD
Xiao-dong Su, MD, PhD
Publication date
01-08-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 8/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07412-w

Other articles of this Issue 8/2019

Annals of Surgical Oncology 8/2019 Go to the issue

ASO Author Reflections

ASO Author Reflections: International Experience of Isolated Limb Infusion for Melanoma Shows Durable Response

Breast Oncology

Sentinel Node Biopsy After Neoadjuvant Systemic Therapy for Breast Cancer: The Method Matters

Hepatobiliary Tumors

Predictors and Cumulative Frequency of Hepatocellular Carcinoma in High and Intermediate LI-RADS Lesions: A Cohort Study from a Canadian Academic Institution

Melanoma

Long–Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis

Colorectal Cancer

Phase II Trial of Neoadjuvant Chemotherapy, Chemoradiotherapy, and Laparoscopic Surgery with Selective Lateral Node Dissection for Poor-Risk Low Rectal Cancer

Breast Oncology

Role of Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer Patients: A Study from the Japanese Breast Cancer Registry